Abstract
Fibrinogen (Fg) has been recognized to play a central role in coagulation, inflammation and tissue regeneration. Several studies have used Fg deficient mice (Fg−/−) in comparison with heterozygous mice (Fg+/−) to point the proinflammatory role of Fg in diverse pathological conditions and disease states. Although Fg+/− mice are considered ‘normal’, plasma Fg is reduced to ∼75% of the normal circulating levels present in wild type mice (Fg+/+). We report that this reduction in Fg protein production in the Fg+/− mice is enough to protect them from kidney ischemia reperfusion injury (IRI) as assessed by tubular injury, kidney dysfunction, necrosis, apoptosis and inflammatory immune cell infiltration. Mechanistically, we observed binding of Fg to ICAM-1 in kidney tissues of Fg+/+ mice at 24 h following IRI as compared to a complete absence of binding observed in the Fg+/− and Fg−/− mice. Raf-1 and ERK were highly activated as evident by significantly higher phosphorylation in the Fg+/+ kidneys at 24 h following IRI as compared to Fg+/− and Fg−/− mice kidneys. On the other hand Cyclin D1 and pRb, indicating higher cell proliferation, were significantly increased in the Fg+/− and Fg−/− as compared to Fg+/+ kidneys. These data suggest that Fg heterozygosity allows maintenance of a critical balance of Fg that enables regression of initial injury and promotes faster resolution of kidney damage.
Introduction
Fibrinogen (Fg) is a 340 kDa glycoprotein, a homodimer linked by disulphide bonds with each unit comprising of 3 distinct polypeptide chains (Aα, Bβ and γ) that are encoded by 3 separate genes (FGA, FGB and FGG) [1]. Apart from its prominent role in the coagulation cascade, Fg serves as an acute phase response protein by acting as a ligand for receptors expressed on cells recruited to the site of inflammation [2]. In humans, several polymorphisms have been described most of them clustered in the FgB gene [3] resulting in chronically elevated levels of Fg [4], [5]. Hyperfibrinogenemia (characterized by high circulating plasma levels of Fg) is consistently associated with an increased risk of cardiovascular diseases [6]; conversely, afibrinogenemia causes severe hemorrhagic risks in affected patients [7]. This suggests the necessity to maintain a critical balance in the levels of Fg that is high enough to maintain adequate clot formation yet low enough to reduce its interactions with cellular receptors along with reducing the availability of fibrin matrices that act as centers of migration and proliferation of immune and endothelial cells in instances of acute and chronic inflammation.
The contribution of Fg in disease pathophysiology of various organs has been studied using Fg deficient mice (Fg−/−) that lack the Aα chain, which precludes assembly of functional circulating protein [8], [9]. Fg deficient mice (Fg−/−) that lack the Aα chain [8] have shown to be protected from variety of injury/disease states such as atherosclerosis [10], colitis [11], crescentric glomerulonephritis [12], Duchenne muscular dystrophy [13], endotoxemia [14], fibrosis [15], [16], multiple sclerosis [17], myocardial ischemia-reperfusion injury [18], ischemic neurodegeneration [19] and rheumatoid arthritis [20]. It should be noted that all of these studies used littermate Fg+/− mice as experimental controls and not as experimental groups for comparison. Although the Fg+/− mice do not show any symptoms of abnormal clotting and are for all purposes ‘normal’ when compared to Fg−/− mice, the plasma level of the Fg protein is reduced to ∼75% of the normal circulating levels present in wild type mice (Fg+/+) [9]. The reduction in Fg may not be significant enough to impair the coagulation cascade but could still suffice to alter the binding response to various cellular receptors thereby transforming the immune system’s inflammatory response.
The objective of our study, therefore, was to evaluate the expression profile of Fg following kidney ischemia reperfusion injury (IRI) and to characterize the phenotype of the Fg−/− and Fg+/− mice against animals homozygous for the Aα gene (Fg+/+) in the context of kidney IRI.
Methods
Ethics
All animal maintenance and treatment protocols were in compliance with the Guide for Care and Use of Laboratory animals as adopted and promulgated by the National Institutes of Health and were approved by the Harvard Medical School Animal Care and Use Committees (IACUC).
Animals
Littermate male wild type (Fg+/+), heterozygous (Fg+/−) and knock out (Fg−/−) mice for fibrinogen on BALB/c background (25–29 g) were used for the experiment [9]. Dr. Jay L. Degen at Children’s Hospital Research Foundation, Cincinnati, Ohio, kindly provided breeding pairs of genetically modified Fg mice. Neonate mice experience spontaneous bleeding events, which proves fatal only in 30–50% of cases (depending on strain) and those who survive display otherwise normal organ physiology [9].
Experimental Design
In the first set of experiments twenty male BALB/c mice were anesthetized using pentobarbital sodium (30 mg/kg, ip) and subjected to 25 min bilateral IRI [21] for characterization of fibrinogen expression and excretion. Mice were sacrificed at 24, 48 and 72 hours after reperfusion (n = 5/timepoint). In the next set of experiments genetically manipulated mice (54 male wild type, heterozygous and knockout mice) were anesthetized as mentioned above and subjected to 29 min of bilateral renal I/R surgery by the retroperitoneal approach. Sham surgery was performed with exposure of both kidneys but without induction of ischemia. Mice (n = 6/group/timepoint) in the respective groups (sham or I/R) were injected with BrdU (50 mg/kg, ip) 3 hr prior to sacrifice. Mice were sacrificed at 12 and 24 h following reperfusion using overdose of pentobarbital (180 mg/kg, ip).
Serum creatinine (SCr) concentrations and blood urea nitrogen (BUN) were measured using a VetScan VS2 (Abaxis, Union City, CA). Plasma Fg (D-Dimer) test was performed by Asserachrom D-Di ELISA kit from Diagnostica Stago, Inc. (Parsippany, NJ) as per manufacturer’s instruction. Urinary Fg levels were measured using commercially available Luminex assay based kit from Millipore (Billerica, MA). Urinary creatinine concentration was used to normalize fibrinogen in order to account for the influence of urinary dilution.
Real Time PCR
Total RNA was extracted by TRIzol reagent (Invitrogen Corporation) as per manufacturer’s protocol. Forward and reverse primer sequences for mouse specific genes were designed using MacVector software (MacVector Inc., Cary, NC) and are listed in Table S1.
In situ Hybridization
Kidney, liver and heart cryosections were washed with TBS and in situ hybridization was performed with universal digoxigenin based in situ hybridization and detection kit as per manufacturer’s instructions (Invitrogen, Carlsbad, CA). The probe sequences used are as follows: Fgα-AAT ATG CAA AGA TAG GCA TCA CCC AGA TTG AAG TAG CTA CTG CCT ACC TGC CTG T; Fgβ-AGT ATA CTC TGT ACG GCT TGA TGG AGG TGT CAG GCT GGA TGA GAT ACA TTT CGG A; Fgγ-CTC AGT GCA TAT GGA ATT GTG GAC TGC ATG CTT ATC AAA TGA ATC TTC TCA TTT C.
Immunofluorescence Staining
Immunostainings in the frozen kidney sections was performed using rat monoclonal anti-F4/80 a kind gift from Dr. Bonventre’s laboratory, BWH, Boston, MA and rat monoclonal anti-BrdU (Cell Signaling Technology, Danvers, MA). The primary antibody was detected using donkey anti rat Cy3 labeled and donkey anti rat FITC labeled secondary antibodies respectively (Jackson ImmunoResearch Laboratories, West Grove, PA). DAPI (Sigma Aldrich, St. Louis, MO) was used for nuclear staining. Apoptosis was measured in kidney tissues by TUNEL assay using the In Situ Cell Death detection kit (Roche Applied Science) according to manufacturer’s instructions [22]. The images were captured by Nikon DS-Qi1Mc camera attached to Nikon eclipse 90i fluorescence microscope using oil immersion objective 60/1.4 NA by Nikon NIS elements AR ver 3.2 software.
Immunoblotting and Immunoprecipitation
Kidney tissues were homogenized in RIPA buffer [50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40, 1 mM PMSF, 1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 1X protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN)] and equal protein (30 µg) was resolved by polyacrylamide gel electrophoresis. For plasma 0.02 µl was loaded on the gel. Proteins were transferred onto nitrocellulose membrane and western blotting was performed with rabbit polyclonal anti-fibrinogen (Dako), mouse monoclonal anti-pERK, anti-ERK2 (BD Biosciences San Diego, CA), anti-Cyclin D1, anti-pRb, anti-β -Actin (Cell Signaling Technology), anti-α-Tubulin (Sigma) and goat polyclonal HRP conjugated anti-mouse albumin (Abcam, Cambridge, MA). HRP conjugated secondary antibodies against mouse, rabbit and goat was purchased from Jackson Immunoresearch (West Grove, PA). For Immunoprecipitation (IP) tissues were lysed in IP buffer (20 mM Tris-HCl pH 8.0, 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM EDTA) containing protease inhibitor cocktail and 300 µg protein was incubated overnight at 4°C with 4 µg of rabbit polyclonal anti-fibrinogen antibody (Dako). Fifty microlitre of protein A/G agarose was added and incubated for 2 h at room temperature. Beads were washed thrice with IP buffer. Immune complex was eluted by adding 1X SDS loading dye and heating at 100°C and western blot was performed to detect ICAM-1 (goat polyclonal, R&D Systems) and goat polyclonal anti-fibrinogen (Nordic lab, The Netherlands).
Statistics
Data are expressed as average + standard error. Statistical difference (p<0.05) as calculated by one-way ANOVA or student’s t-test. P<0.05 was considered significant and represented by ‘*’ as compared to shams, ‘#’ as compared to wild type at similar time points, ‘!’ as compared to heterozygous at similar time points where applicable. All graphs were generated by GraphPad Prism (GraphPad, Inc., La Jolla, CA).
Results
We found a significant increase in the mRNA (Fig. 1A, 1B), protein expression (Fig. 1C) of Fg (Fgα, Fgβ and Fgγ) in the kidney and urinary excretion of Fg (Fig. 1D) in mice following IRI corresponding to the kidney dysfunction and proximal tubular necrosis (Fig. S1). In situ hybridization (ISH) with Fgα, Fgβ and Fgγ in the liver tissue revealed strong diffuse cytoplasmic staining in the hepatocytes (Fig. 1B, biological positive control). In the kidney, the staining varied in intensity and distribution between the chains and with respect to the presence or absence of injury (Fig. 1B, first two columns). Fgα in uninjured (sham) kidney revealed diffuse cytoplasmic staining that was less intense than the reactivity in liver under the same conditions. The staining was more intense and perinuclear in distribution 24 h after IRI. The staining was more intense and perinuclear in distribution 24 h after IRI. ISH for Fgβ in uninjured kidney was as intense as in liver, but revealed more intense diffuse cytoplasmic distribution at 24 h. ISH for Fgγ was of similar reactivity to Fgα in distribution and intensity, in uninjured and injured kidney; there was more diffuse cytoplasmic staining in uninjured tissue, with less intense reactivity when compared to the liver tissue, but in IRI, the reactivity intensified and distributed around the nuclei, similar to the Fgα.
Phenotypically the Fg+/+, and mutant mice for FgA-α chain [heterozygous (Fg+/−) or knockout (Fg−/−)] demonstrated following features (Fig. S2A): i) loss of Fgα chain with, albeit modestly decreased, but detectable transcription and translation of Fgβ and Fgγ chains in the liver of Fg−/− mice (Fig. S2B) as reported previously [9]; ii) significant decrease in transcription and translation of Fgα and Fgβ with no alterations in Fgγ chain in the kidney of Fg−/− mice (Fig. S2C) as compared to Fg+/+ mice; iii) approximately 50% decrease in plasma Fg D-Dimer levels in Fg+/− mice and undetectable Fg protein in the circulation in Fg−/− mice as compared to Fg+/+ (Fig. S2D); iv) unaltered urinary Fg protein excretion (Fig. S2E).
Following IRI, Fg+/− and Fg−/− mice showed greater kidney dysfunction as assessed by BUN and SCr (Fig. 2A) at 12 h as compared to Fg+/+ mice (Fig. 2A). However, by 24 h the kidney dysfunction in the Fg+/+ and Fg−/− mice further escalated whereas, the Fg+/− mice appeared to show rapid functional restoration with BUN and SCr levels ∼2–3 fold lower than the Fg+/+ and Fg−/− mice (Fig. 2A). Urinary Fg, serving as a sensitive indicator of kidney tubular injury [21], also showed a massive increase at 12 h in all three groups but significantly reduced levels in Fg+/− (∼5-fold) and Fg−/− (∼10- fold) mice at 24 h as compared to Fg+/+ mice (Fig. 2A). Kidney histology showed severe necrosis in the cortico-medullary junction of all post ischemic kidneys particularly in the S3 segments at 12 and 24 h (Fig. 2B). Although differences between the Fg+/+, Fg+/− and Fg−/− mice in the extent of necrosis were subtle, there was a marked reduction in the number of apoptotic cells at 24 h in the Fg+/− and Fg−/− mice as compared to Fg+/+ mice (Fig. 2C).
We next evaluated the contribution of inflammatory immune cell invasion in progression of kidney injury by immunostaining for markers of macrophage (F4/80) and neutrophil (Ly-6G) infiltration. The number of F4/80 positive cells was similar at 12 h in all three groups but at 24 h the Fg+/− and Fg−/− mice showed a statistically significant decrease in the number of macrophages (Fig. 3A) as well as Ly-6G positive neutrophils (Fig. S3) as compared to Fg+/+ mice.
To evaluate the kidney tissue repair we quantitated the number of proliferating epithelial cells by BrdU immunostaining and found that Fg+/− and Fg−/− mice exhibited significantly greater number of BrdU positive cells as compared to Fg+/+ mice at 24 h (Fig. 3B). This suggests that although the initiation and early phase of injury was similar in all three groups there was a timely and efficient tissue repair response in the Fg+/− and Fg−/− mice, which curbed inflammation and apoptosis resulting in regression of injury. We hypothesized that in the Fg+/+ mice there is progression of the initial injury because of Fg binding to Intercellular Adhesion Molecule-1 (ICAM-1) that promotes apoptosis and cell death through ERK phosphorylation.
We found that there was significant binding of Fg to ICAM-1 in kidney tissues of Fg+/+ mice at 24 h following IRI as compared to a complete absence of binding observed in the Fg+/− and Fg−/− mice (Fig. 4A). Consistently there was a significant decrease in expression of Fg protein at 24 h in Fg+/− and Fg−/− mice kidneys as compared to Fg+/+ mice following IRI (Fig. 4B). We further confirmed Fg binding to ICAM-1 in tubular epithelial cells by co-immunostaining that showed a Pearson co-localization coefficient between Fg and ICAM-1 to be 0.6 in Fg+/+ as compared to 0.4 and 0.05 in Fg+/− and Fg−/− respectively (Fig. S4). Raf-1 and ERK were highly activated as evident by significantly higher phosphorylation in the Fg+/+ kidneys at 24 h following IRI as compared to Fg+/− and Fg−/− mice kidneys. pERK was upregulated at 12 h in all three groups confirming the earlier observations (Fig. 2) about similar level of necrosis, apoptosis and inflammation at 12 h in the three groups of mice. On the other hand Cyclin D1 and pRb, indicating higher cell proliferation, were significantly greater at 24 h in the Fg+/− and Fg−/− as compared to Fg+/+ kidneys (Fig. 4B).
Discussion
Our results support the hypothesis that a reduction in availability of excess Fg from interacting with ICAM-1 prevents progression of injury thereby allowing timely induction of Cyclin D1 and pRb mediating efficient kidney tissue repair and resolution of injury (Fig. 4C). This hypothesis is consistent with the previous reports demonstrating therapeutic potential of Fg-derived peptides (Bβ15–42 and γ377–395) by competing with native Fg for binding to vascular endothelial cadherin (VE-cadherin), ICAM-1, CD11b/CD18 which in turn inhibits infiltration of leukocytes at the site of injury and prevents exacerbation of injury [18], [23]. Furthermore, others and we have previously shown that Bβ15–42 peptide administration protected from kidney IRI by increasing tissue repair and decreasing apoptosis [21], [24] confirming that pharmacological reduction in excess Fg paves the way for faster structural and functional recovery.
Thus, the new findings of this study are i) Fg (Fgα, Fgβ, and Fgγ) is transcribed in the kidney and its mRNA levels, protein expression and urinary excretion significantly increase following IRI; ii) Heterozygosity of mouse FgAα chain results in global reduction of Fg production to a moderate level that protects the Fg+/− mice from IRI-induced kidney tubular injury, kidney dysfunction, inflammation and apoptosis by launching an efficient tissue regeneration response. Although Fg−/− mice showed a reduction in apoptosis, reduced immune cell infiltration and increased regeneration, the functional and structural restoration of the kidney after IRI was not as rapid as Fg+/− mice potentially due to the impedance with clotting.
Fibrinogen binding to ICAM-1 through its γ117–133 domain has been well documented on endothelial cells [25], [26] and has been shown to promote leukocyte transmigration by acting as an intermediary molecule that can bind both ICAM-1 and leukocytes through the Mac-1 receptor [27]. We extended these studies and show that Fg binds to ICAM-1 in the kidney following IRI thereby potentially activating Raf-1, triggering the Raf-MEK-ERK pathway, which in turn can activate an apoptotic response. Experiments using anti-ICAM-1 antibodies as well as ICAM-1–deficient mice have shown ICAM-1 to be a key mediator of acute IRI injury via potentiation of neutrophil–endothelial interactions [28]. ICAM-1 expression significantly increases on proximal tubular epithelial cells in patients with acute renal allograft rejection [29] and here we found significant co-localization of ICAM-1 with Fg (Pearson’s co-localization coefficient of 0.6, Fig. S4) predominantly on the proximal tubular epithelial cells emphasizing the paradigm that tubular epithelium is not merely a passive victim of injury but also an active participant in the inflammatory response in kidney IRI [30].
In summary, our experiment shows that kidney expresses Fgα, Fgβ and Fgγ transcripts and genetic manipulation resulting in decreased availability of Fg protein to interact with cellular receptors diminishes the molecular response cascade and dampens the inflammatory response leading to faster resolution of injury.
Supporting Information
Acknowledgments
We thank Dr. Jay L. Degen, Professor, Department of Pediatrics, Children’s Hospital Research Foundation, Cincinnati, Ohio, for providing breeding pairs of genetically modified mice for fibrinogen α chain. We thank Dr. Joseph V. Bonventre, Director, Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA for kindly providing the F4/80 antibody.
Funding Statement
This work in Vaidya laboratory was supported by National Institutes of Health/National Institute of Environmental Health Sciences Outstanding New Environmental Scientist Award (ES017543). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Fuller GM, Zhang Z (2001) Transcriptional control mechanism of fibrinogen gene expression. Ann N Y Acad Sci 936: 469–479. [DOI] [PubMed] [Google Scholar]
- 2. Doolittle RF (1984) Fibrinogen and fibrin. Annu Rev Biochem 53: 195–229. [DOI] [PubMed] [Google Scholar]
- 3. Iacoviello L, Vischetti M, Zito F, Benedetta Donati M (2001) Genes encoding fibrinogen and cardiovascular risk. Hypertension 38: 1199–1203. [DOI] [PubMed] [Google Scholar]
- 4. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, et al. (1996) Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l’Infarctus du Myocarde. Circulation 93: 440–449. [DOI] [PubMed] [Google Scholar]
- 5. Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, et al. (1993) Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb 13: 886–891. [DOI] [PubMed] [Google Scholar]
- 6. Reinhart WH (2003) Fibrinogen–marker or mediator of vascular disease? Vasc Med 8: 211–216. [DOI] [PubMed] [Google Scholar]
- 7. Peyvandi F, Haertel S, Knaub S, Mannucci PM (2006) Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 4: 1634–1637. [DOI] [PubMed] [Google Scholar]
- 8. Degen JL, Drew AF, Palumbo JS, Kombrinck KW, Bezerra JA, et al. (2001) Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann N Y Acad Sci 936: 276–290. [DOI] [PubMed] [Google Scholar]
- 9. Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, et al. (1995) Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 9: 2020–2033. [DOI] [PubMed] [Google Scholar]
- 10. Iwaki T, Sandoval-Cooper MJ, Brechmann M, Ploplis VA, Castellino FJ (2006) A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice. Blood 107: 3883–3891. [DOI] [PubMed] [Google Scholar]
- 11. Steinbrecher KA, Horowitz NA, Blevins EA, Barney KA, Shaw MA, et al. (2010) Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res 70: 2634–2643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Drew AF, Tucker HL, Liu H, Witte DP, Degen JL, et al. (2001) Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am J Physiol Renal Physiol 281: F1157–1163. [DOI] [PubMed] [Google Scholar]
- 13. Vidal B, Serrano AL, Tjwa M, Suelves M, Ardite E, et al. (2008) Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev 22: 1747–1752. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Cruz-Topete D, Iwaki T, Ploplis VA, Castellino FJ (2006) Delayed inflammatory responses to endotoxin in fibrinogen-deficient mice. J Pathol 210: 325–333. [DOI] [PubMed] [Google Scholar]
- 15. Sorensen I, Susnik N, Inhester T, Degen JL, Melk A, et al. (2011) Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int 80: 1035–1044. [DOI] [PubMed] [Google Scholar]
- 16. Wilberding JA, Ploplis VA, McLennan L, Liang Z, Cornelissen I, et al. (2001) Development of pulmonary fibrosis in fibrinogen-deficient mice. Ann N Y Acad Sci 936: 542–548. [DOI] [PubMed] [Google Scholar]
- 17. Akassoglou K, Adams RA, Bauer J, Mercado P, Tseveleki V, et al. (2004) Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci U S A 101: 6698–6703. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Petzelbauer P, Zacharowski PA, Miyazaki Y, Friedl P, Wickenhauser G, et al. (2005) The fibrin-derived peptide Bbeta15–42 protects the myocardium against ischemia-reperfusion injury. Nat Med 11: 298–304. [DOI] [PubMed] [Google Scholar]
- 19. Adhami F, Liao G, Morozov YM, Schloemer A, Schmithorst VJ, et al. (2006) Cerebral ischemia-hypoxia induces intravascular coagulation and autophagy. Am J Pathol 169: 566–583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, et al. (2007) Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest 117: 3224–3235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Krishnamoorthy A, Ajay AK, Hoffmann D, Kim TM, Ramirez V, et al. (2011) Fibrinogen {beta}-derived B{beta}15–42 peptide protects against kidney ischemia/reperfusion injury. Blood 118: 1934–1942. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Krishnamoorthy A, Clement ME, O’Leary E, Bonventre JV, Vaidya VS (2010) TIM2 gene deletion results in susceptibility to cisplatin-induced kidney toxicity. Toxicological sciences : an official journal of the Society of Toxicology 118: 298–306. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Adams RA, Bauer J, Flick MJ, Sikorski SL, Nuriel T, et al. (2007) The fibrin-derived gamma377–395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 204: 571–582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Sorensen I, Rong S, Susnik N, Gueler F, Shushakova N, et al. (2011) Bbeta(15–42) attenuates the effect of ischemia-reperfusion injury in renal transplantation. J Am Soc Nephrol 22: 1887–1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Altieri DC, Duperray A, Plescia J, Thornton GB, Languino LR (1995) Structural recognition of a novel fibrinogen gamma chain sequence (117–133) by intercellular adhesion molecule-1 mediates leukocyte-endothelium interaction. J Biol Chem 270: 696–699. [DOI] [PubMed] [Google Scholar]
- 26. Languino LR, Plescia J, Duperray A, Brian AA, Plow EF, et al. (1993) Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 73: 1423–1434. [DOI] [PubMed] [Google Scholar]
- 27. Languino LR, Duperray A, Joganic KJ, Fornaro M, Thornton GB, et al. (1995) Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc Natl Acad Sci U S A 92: 1505–1509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, et al. (1996) Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 97: 1056–1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Jeong HJ, Lee HH, Kim YS, Kim SI, Moon JI, et al. (1998) Expression of ICAM-1 and VCAM-1 in renal allograft rejection. Transplant Proc 30: 2953–2954. [DOI] [PubMed] [Google Scholar]
- 30. Bonventre J, Yang L (2011) Cellular pathophysiology of ischemic acute kidney injury. The Journal of clinical investigation 121: 4210–4231. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.